	US 12,215,170 B2
	Anti-TMPRSS6 antibodies and uses thereof
Xin Du, La Jolla, CA (US); Buxin Chen, San Marcos, CA (US); and Yu Jean Wang, San Diego, CA (US)
Assigned to MABWELL THERAPEUTICS INC., San Diego, CA (US)
Appl. No. 17/916,008
Filed by MABWELL THERAPEUTICS INC., San Diego, CA (US)
PCT Filed Apr. 5, 2021, PCT No. PCT/US2021/025775 § 371(c)(1), (2) Date Sep. 29, 2022, PCT Pub. No. WO2021/207072, PCT Pub. Date Oct. 14, 2021.
Claims priority of provisional application 63/158,265, filed on Mar. 8, 2021.
Claims priority of provisional application 63/006,695, filed on Apr. 7, 2020.
Prior Publication US 2023/0203196 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); A61P 7/06 (2006.01); C12N 15/63 (2006.01)

CPC C07K 16/40 (2013.01) [A61P 7/06 (2018.01); C12N 15/63 (2013.01); C07K 2317/565 (2013.01)]

20 Claims

1. An anti-type II transmembrane serine protease 6 (TMPRSS6) antibody comprising a HC CDR1, a HC CDR2, and a HC CDR3 of a heavy chain variable region (VH) that comprises the amino acid sequence of SEQ ID NO: 21 or 51, and a LC CDR1, a LC CDR2, and a LC CDR3 of a light chain variable region (VL) of SEQ ID NO: 26 or 56.